Furthermore, a recent study reported that cenicriviroc (CVC), a dual CCR2 and CCR5 antagonist, was used in a phase IIb clinical trial involving 289 adult patients with nonalcoholic steatohepatitis (NASH) and fibrosis. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.